Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 93Terminated 36Unknown 12Withdrawn 4Active not recruiting 3Recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Shwachman-Diamond Syndrome 1Primary Immunodeficiency Diseases 1Neutropenia, Severe Congenital, Autosomal Recessive 3 1Myelodysplastic Syndromes 1Macrophage Activation Syndrome 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Histiocytosis, Langerhans-Cell 1Histiocytosis 1Hemoglobinopathies 1Bone Marrow Failure Disorders 1Anemia, Sickle Cell 1Anemia, Diamond-Blackfan 1Anemia, Aplastic 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Alemtuzumab × Clear all
NCT03821610 2026-05-05

ALL-RIC

University of Birmingham

Phase 2 Active not recruiting
242 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01361711 2025-05-23

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Northwestern University

Phase 2 Active not recruiting
53 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Columbia University

Phase 1/2 Active not recruiting
14 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Neutropenia, Severe Congenital, Autosomal Recessive 3, Bone Marrow Failure Disorders, Shwachman-Diamond Syndrome, Primary Immunodeficiency Diseases, Acquired Immunodeficiency Syndrome, Anemia, Aplastic, Anemia, Sickle Cell, Hemoglobinopathies, Histiocytosis, Langerhans-Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Histiocytosis, Anemia, Diamond-Blackfan, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Macrophage Activation Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡